Novo Nordisk is partnering with telehealth providers Hims & Hers, Ro, and Life MD to make its weight loss drug Wegovy more accessible. Shares soar as Wegovy becomes readily available.
In a pivotal court ruling, Judge Mark Pittman denied compounding pharmacies' request for an injunction against the FDA's decision on the semaglutide shortage. This ruling keeps strict timelines for exiting the market, leaving many in the industry concerned.
Eli Lilly introduces discounted higher doses of the weight loss drug Zepbound in a move to make the treatment more accessible to uninsured patients and address the growing demand for obesity treatments.
